Date of Award

4-19-2024

Document Type

Honors Thesis

Department

Biology

First Advisor

Denise L. Smith

Second Advisor

Desmond H. Murray

Abstract

Glioblastoma is treated with Temozolomide (TMZ), a lipophilic alkylating drug that can cross the brain-blood barrier. To confront drug resistance, this research aimed to synthesize novel TMZ amide hybrids by using the acid chloride method, replacing an amino group with a primary amine. These novel hybrids were tested on U87-MG cells to determine if the primary amines with greater anticancer properties and lipophilicity have enhanced the drug's anticancer activity and bioavailability. The calculated lethal concentration 50 (LC50) of the hybrids ranged from 0.005 mg/mL to 0.2258 mg/mL, with some demonstrating greater anticancer effects than TMZ itself.

Subject Area

Gliomas; Alkylating agents; Amines

Files over 3MB may be slow to open. For best results, right-click and select "save as..."

Share

COinS